Destiny Pharma PLC Notice of Interim Results (3225J)
23 Agosto 2021 - 01:00AM
UK Regulatory
TIDMDEST
RNS Number : 3225J
Destiny Pharma PLC
23 August 2021
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Notice of Interim Results and Investor Presentation
Brighton, United Kingdom - 23(rd) August 2021 - Destiny Pharma
plc (AIM: DEST), a clinical stage innovative biotechnology company
focused on the development of novel medicines that can prevent life
threatening infections, will announce its Interim Results for the
period ended 30(th) June 2021, on Thursday 9(th) September
2021.
Neil Clark, Chief Executive Officer and Shaun Claydon, Chief
Financial Officer, will provide a live presentation on the same
day, at 09:30 am BST, followed by a Q&A session accessible via
the Investor Meet Company platform. The webcast of the presentation
will be available on the Company's investor relations website at
www.destinypharma.com .
The presentation is open to analysts and all existing and
potential new shareholders. Questions can be submitted pre-event
via the Investor Meet Company Dashboard up until 09:00 am BST the
day before the meeting, or at any time during the live
presentation.
Investors can sign up to Investor Meet Company for free, and add
to meet Destiny Pharma plc via:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
Investors who already follow Destiny Pharma plc on the Investor
Meet Company platform will automatically be invited.
-END-
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark / Hollie Vile / Manel Mateus
DestinyPharma@optimumcomms.com
+44 (0) 208 078 4357
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information, please visit www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSEASUSEFSEEA
(END) Dow Jones Newswires
August 23, 2021 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024